person · Reporting owner
SCANNON PATRICK J MD PHD
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | May 23, 2025 | July 16, 2025 |
| XOMA Royalty CorpXOMA · Entity 30207 | Exec. VP & CSO · Exec. VP & CSO | December 21, 2016 | December 23, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date May 23, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2035-05-23 | Direct | 26,500 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 26,500 · Balance 26,500 F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. |
Filing footnotes · ownership attribution and instrument terms
F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month.
XOMA Royalty Corp
Report date December 21, 2016 · Filed December 23, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 8,217 |
Reported balance
After 2016-12-21 transaction · row 1
1 source rowRow 1 · 2016-12-21 · Sale · Disposed 3,230 · Balance 8,217 F1: Shares sold on the open market to satisfy the taxes required to be withheld in connection with the vesting of the shares in a non-discretionary transaction pursuant to the reporting person's agreement under the Company's incentive plan. |
| Common SharesSEC Table I · non-derivative | Indirectby 401(k) | 1,690 |
Reported balance
Holding disclosure · report date 2016-12-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,690 |
| Common SharesSEC Table I · non-derivative | Indirectby Daughter | 37 |
Reported balance
Holding disclosure · report date 2016-12-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 37 |
| Common SharesSEC Table I · non-derivative | Indirectby Trust | 202 |
Reported balance
Holding disclosure · report date 2016-12-21 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 202 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold on the open market to satisfy the taxes required to be withheld in connection with the vesting of the shares in a non-discretionary transaction pursuant to the reporting person's agreement under the Company's incentive plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2025 Filed Jul 16, 2025 20:04 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 26,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001437749-25-022829 · rdgdoc.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2035-05-23 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:14 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001437749-24-016242 · rdgdoc.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-09 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 20:53 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.95 Strike: $0.95 | $950.00 |
DisclosureSEC source: 0001069530-23-000037 · certent-form4.xml · derivative · entry 2 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,000 shares Expires 2028-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 20:53 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 1,000 | $0.95 | $950.00 |
DisclosureSEC source: 0001069530-23-000037 · certent-form4.xml · nonDerivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:14 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $22.34 Strike: $22.34 | $446,800.00 |
DisclosureSEC source: 0001069530-23-000031 · certent-form4.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: Stock options vest over a three (3) year period at a rate of 1/36th per month. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 22:08 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001069530-20-000077 · certent-form4.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-12-11 F1 · derivative.exercise_date: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:03 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001069530-19-000057 · certent-form4.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:38 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantStock Options(1) · Derivative | 10,000 | $0.95 Strike: $0.95 | $9,500.00 |
DisclosureSEC source: 0001069530-18-000047 · primary_doc.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 10,000 shares Expires 2028-09-14 Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:27 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantNon-Qualifying Stock Options (1) · Derivative | 20,000 | $4.09 Strike: $4.09 | $81,800.00 |
DisclosureSEC source: 0001069530-17-000044 · primary_doc.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,204 Underlying: Common Stock · 20,000 shares Expires 2027-12-06 Read SEC document |
| May 04, 2017 Filed May 5, 2017 21:04 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantNon-Qualifying Stock Options (1) · Derivative | 50,000 | $0.78 Strike: $0.78 | $39,000.00 |
DisclosureSEC source: 0001573723-17-000005 · primary_doc.xml · derivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,128 Underlying: Common Stock · 50,000 shares Expires 2027-05-04 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 23:36 UTC | XOMA Royalty Corp XOMA · Entity 30207 | SaleCommon Shares | 3,230 | $5.75 | $18,572.50 |
DisclosureSEC source: 0000791908-16-000180 · edgardoc.xml · nonDerivative · entry 1 SCANNON PATRICK J MD PHD · CIK 0001222790 · Exec. VP & CSO · Exec. VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,217 F1 · kind: Shares sold on the open market to satisfy the taxes required to be withheld in connection with the vesting of the shares in a non-discretionary transaction pursuant to the reporting person's agreement under the Company's incentive plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.